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Abstract
Background: Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission.
We assessed NVP-resistance in Indian infants enrolled in the ‘‘six-week extended-dose nevirapine’’ (SWEN) trial who received
single-dose NVP (SD-NVP) or SWEN for prevention of breast-milk HIV transmission but who also acquired subtype C HIV
infection during the first year of life.
Methods/Findings: Standard population sequencing and cloning for viral subpopulations present at $5% frequency were
used to determine HIV genotypes from 94% of the 79 infected Indian infants studied. Timing of infection was defined based
on when an infant’s blood sample first tested positive for HIV DNA. SWEN-exposed infants diagnosed with HIV by six weeks
of age had a significantly higher prevalence of NVP-resistance than those who received SD-NVP, by both standard
population sequencing (92% of 12 vs. 38% of 29; p=0.002) and low frequency clonal analysis (92% of 12 vs. 59% of 29;
p=0.06). Likelihood of infection with NVP-resistant HIV through breast-milk among infants infected after age six weeks was
substantial, but prevalence of NVP-resistance did not differ among SWEN or SD-NVP exposed infants by standard
population sequencing (15% of 13 vs. 15% of 20; p=1.00) and clonal analysis (31% of 13 vs. 40% of 20; p=0.72). Types of
NVP-resistance mutations and patterns of persistence at one year of age were similar between the two groups. NVP-
resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in
the first six weeks of life, compared to Y188C/H during late breast-milk transmission.
Conclusions/Significance: Use of SWEN to prevent breast-milk HIV transmission carries a high likelihood of resistance if
infection occurs in the first six weeks of life. Moreover, there was a continued risk of transmission of NVP-resistant HIV
through breastfeeding during the first year of life, but did not differ between SD-NVP and SWEN groups. As with SD-NVP,
the value of preventing HIV infection in a large number of infants should be considered alongside the high risk of resistance
associated with extended NVP prophylaxis.
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Introduction
In 2007, an estimated 420,000 infants worldwide were infected
with human immunodeficiency virus (HIV) through in utero,
peripartum, or breast-milk transmission [1]. Antiretroviral drugs
and avoidance of breastfeeding can reduce the risk of mother-to-
child transmission (MTCT) of HIV to less than 2% [2,3] from 25–
35% [4]. Single-dose nevirapine (SD-NVP), used to help prevent
perinatal HIV infection in resource-constrained settings, reduces
transmission by 50% but has limited effect on subsequent breast-
milk transmission [5].
The overall risk of HIV transmission through breastfeeding is
estimated to be 10%, with the greatest risk by the first six to 14
weeks of life, a period in which 60–70% of breast-milk
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Organization (WHO) recommends that HIV-infected mothers
exclusively breastfeed for at least six months to improve infant
survival [7,8]. To maintain breastfeeding and reduce transmission
risk, nevirapine (NVP) dosing could be extended into the period of
greatest risk. Two recently completed randomized controlled trials
showed that daily dosing of NVP for up to six weeks of age (‘‘six
week extended-dose NVP’’ [SWEN] trial) or NVP with or without
zidovudine (AZT) administered to 14 weeks of age (PEPI-Malawi
trial) reduced breast-milk transmission by 46% and 66%,
respectively [9,10].
It is known, however, that SD-NVP prophylaxis comes with the
risk of drug resistance if prevention fails. Pooled estimates showed
that 36% (19–76%) of women and 53% (36–87%) of infants have
detectable NVP resistance (NVP-R) mutations 6–8 weeks after
exposure to SD-NVP [11]. Importantly, these mutations decrease in
frequencyby12–18monthsfollowingexposuretoSD-NVP,andcan
nolongerbedetectedbystandardpopulationsequencing[12,13,14],
and detection requires more sensitive assays [15,16,17]. The
selection of NVP-R after SD-NVP may reduce the likelihood of
achieving virologic suppression with NVP-containing highly active
antiretroviral therapy (HAART) regimens, although the impact on
treatment outcomes remains unclear [18,19].
Ugandan infants receiving extended daily NVP prophylaxis and
diagnosed with subtypes A or D infection the first six weeks of life
have been observed to have a higher risk of drug resistance than
infants receiving SD-NVP [20]. However, the risk of NVP-R
arising as a result of unsuccessful daily NVP prophylaxis in subtype
C infected infants is not known, nor is the continuing risk from
breast-milk transmission after prophylaxis during the first year of
life. And, while it is generally true that SD-NVP exposure results in
a lower risk of drug resistance in HIV subtype A or D infected
individuals than for those infected with subtype C [21], the relative
effect of extended NVP prophylaxis on resistance among HIV
subtypes is not known. To address these questions, we compared
the prevalence of NVP-R mutations following administration of
single- or extended-dose NVP to subtype C infected Indian infants
enrolled in the SWEN trial who became infected despite
prophylaxis, and in whom the timing and mode of HIV infection
were determined.
Methods
Study Participants and Intervention
The SWEN trial was conducted in Ethiopia, India, and Uganda
from February 2001 to March 2007 [10]. Informed consent was
obtained as part of the parent trial as described previously [10].
Briefly, written informed consent was obtained where possible;
and verbal consent was obtained when subjects were unable to
read and subsequently documented in writing by a witness. HIV
drug resistance testing was performed on de-identified Indian
plasma samples shipped to Johns Hopkins University for analysis
and approved by the Johns Hopkins Institutional Review Board.
In this trial, HIV-infected pregnant women cared for at Byramjee
Jeejeebhoy Medical College in Pune, India, were enrolled during
their antenatal visit, at delivery, or within one week post-partum.
Women enrolled before delivery were offered short-course AZT
[22] in addition to SD-NVP for prevention of MTCT of HIV, but
acceptance was the individual’s choice [10]. Infants were
randomized at birth to receive SD-NVP plus multivitamins, or
5 mg of NVP once daily with multivitamins from one week to six
weeks of age [10]. To limit exposure of an HIV-infected infant to
monotherapy with NVP, study drugs were discontinued once HIV
infection was detected. HIV-infected infants were treated
according to local clinical care guidelines [23]. Overall, 34% of
730 women did not receive intrapartum SD-NVP, primarily
because they were unaware of their HIV status at the time of
delivery and were enrolled post-partum.
Estimation of the Timing and Mode of Infection
Blood samples were collected to determine HIV infection status in
infants at 48 hours, weeks 1, 2, 4, 6, 10, 14 and months 6, 9 and 12
through detection of HIV DNAbypolymerasechain reaction (PCR)
using a validated in-house assay [24]. HIV quantitative RNA testing
(Roche Amplicor HIV Monitor test version 1.5, F. Hoffmann-La
Roche Ltd, Basel, Switzerland) was used to confirm infection at the
next scheduled study visit. Based on the time of first positive HIV
DNA PCR, infants were assigned to one of the following categories
reflecting the mode of infection: in utero (positive by 48 hours);
peripartum/early-breastfeeding (positive from weeks one through
six); late-breastfeeding (positive after six weeks).
Genotyping
Infants were only included in the analysis of NVP-R mutations
if plasma samples for genotyping were available at the first positive
HIV DNA PCR test (n=13) or the first (n=43) or second (n=18)
subsequent visits. Unlike other studies of SD-NVP prophylaxis,
analysis of NVP-R at a fixed age after NVP exposure could not be
performed in the Indian cohort because plasma samples were
collected sequentially only until the diagnosis of HIV was
confirmed, after which plasma samples were not collected at
regular intervals. The median age at genotyping for infants
diagnosed with HIV in the first six weeks of life for the cohort was
29 days (interquartile range [IQR]: 22–43 days). Seven SD-NVP
exposed women who transmitted HIV during late-breastfeeding
and who had plasma samples available at six months after delivery
were also genotyped. HIV genotyping was performed by standard
population sequencing, which detects mutant viral subpopulations
present at .20% frequency [25,26] using a previously published
assay [27]. Sequences were assembled in Bioedit Version 7, and
mutation errors from PCR amplification were removed [28].
Phylogenetic trees were constructed by neighbor-joining method
(1000 bootstrap permutations) using Mega Version 4.0 [29] with
HIV subtype B and C reference sequences from the Los Alamos
HIV database [30] to determine patient specificity and genetic
relatedness between infant and maternal sequences. NVP-R was
defined by mutations present at the following amino acid sites:
L100I, K101E/P, K103N/S, V106A/M, V108I, Y181C/I/V,
Y188C/L/H, or G190A/S/E based on recommendations from
International AIDS Society-USA Drug Resistance Mutations and
Stanford University drug-resistance database [31,32]. Nucleotide
sequences have been deposited in GenBank, and the accession
numbers are FJ520232 to FJ524294.
Low Frequency Variant Analysis
For infants diagnosed with HIV infection within the first 14
weeks of life and in whom NVP-R mutations were not detected by
standard population sequencing, extensive cloning was used to
detect mutant viral subpopulations present at $5% [14]. PCR-
amplified products were cloned into TOPO cloning vectors
(Invitrogen, Carlsbad, CA), and up to 96 clones per subject were
selected for sequencing on an ABI 3730 sequencer (Agencourt
Bioscience Corporation, Beverly, MA). Low frequency variant
analysis was also performed on: infants infected after 14 weeks of
age who had wild-type HIV infection by standard population
sequencing and whose mothers received SD-NVP, the seven
mothers with available samples collected six months postpartum
who transmitted HIV through late-breastfeeding, and also on 10
Nevirapine Resistance
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by standard population sequencing at first analysis and had follow-
up samples for assessing persistence of NVP-R.
Statistical Analysis
The outcome reported here, as prespecified in the original trial
protocol, was to compare NVP-R by timing and mode of HIV
infection among infants who received SD-NVP or SWEN for
prevention of breast-milk HIV transmission. However, an ‘‘as-
treated’’ analysis instead of an intent-to-treat analysis was
performed to evaluate NVP exposure on resistance outcomes in
infants. Additional outcomes assessed were types of NVP-R
mutations, patterns and prevalence of persistence of NVP-R
mutations, and genotypes from seven SD-NVP exposed women six
months postpartum whose infants became infected during late
breastfeeding. Characteristics of mothers and infants in each
intervention group were compared using Fisher’s exact test for
categorical variables and Mann-Whitney test for continuous
variables. Data analyses were performed using STATA software,
version 10.0 (StataCorp LP, College Station, TX).
Results
NVP-R analysis was performed on 74 of 96 (77%) HIV subtype
C infected Indian infants in the SWEN trial. Samples were missing
from 17 infants (18%) who were either lost to follow-up (n=4),
died (n=1), or had insufficient or no available plasma sample
within two visits of diagnosis of HIV infection (n=12). HIV-1
genotyping was successful in 74 of 79 (94%) evaluable infants. Of
these 74 infants, 55% were infected in utero (n=22) or through
peripartum/early-breastfeeding transmission (n=19), and 45%
were infected through late-breastfeeding (n=33). While analysis of
NVP-R was not performed at a fixed age for the cohort, the
median age at genotyping was similar to other published studies of
NVP-R following SD-NVP exposure [11]. For infants infected in
utero and through peripartum/early-breastfeeding, the median age
at genotyping was 22 days (IQR: 17–28 days) and 43 days (IQR:
30–71 days), respectively. For those infected through late-
breastfeeding, the median age at genotyping was 189 days (IQR:
182–368 days) with a median interval between HIV diagnosis and
genotyping of 39 days (IQR: 28–89 days). Infants randomized to
SWEN received study drugs for a median of 14 days (IQR: 9–15
days) in the in utero group; 29 days (IQR: 22–35 days) in
peripartum/early-breastfeeding group; and 35 days (IQR: 33–35
days) in late-breastfeeding group. Two SWEN-exposed infants
diagnosed with infection in the first six weeks of life were still
receiving NVP when genotyping was performed. Phylogenetic
analyses confirmed that infant sequences were patient-specific and
co-mingled with HIV subtype C Indian reference sequence and
corresponding maternal sequences (data not shown).
Drug resistance was therefore assessed in 25 infants who
received SWEN and in 49 infants who received SD-NVP. A
higher proportion of mothers of infants who received SWEN were
started on combination antiretroviral therapy prior to or following
delivery than mothers of infants who received SD-NVP (32% vs.
8%; p=0.02) (Table 1). Most women (11 of 12) in both groups
were treated after delivery; however, genotypes in 10 of the 11
corresponding infants were obtained prior to initiation of maternal
antiretroviral therapy and did not likely influence the resistance
outcomes in these infants.
In an ‘‘as-treated’’ analysis, we found that infants diagnosed
with HIV infection in the first six weeks of life who received
SWEN were significantly more likely to have NVP-R mutations
detected by standard population sequencing compared to infants
who received SD-NVP (92% of 12 vs. 38% of 29; p=0.002;
Figure 1). Exclusion of the 22 infants infected in utero (who had
established HIV infection at birth, could not have benefited from
the intervention, and might be expected to have higher prevalence
of drug resistance), showed that infants infected through
peripartum/early-breastfeeding who received SWEN were also
significantly more likely to have NVP-R mutations than infants
who received SD-NVP (100% of 4 vs. 27% of 15; p=0.008).
However, since standard population sequencing underestimates
prevalence of NVP-R arising during prophylaxis, we identified
Table 1. Infant and maternal characteristics by infant intervention.
Infant and Maternal Characteristics SWEN (n=25) SD-NVP (n=49) p-value*
Male 13 (52) 24 (49) 0.81
Median Birth Weight (grams [IQR]) 2600 (2500, 3000) 2500 (2250, 2950) 0.36
Preterm Birth 2 (8) 11 (22) 0.20
Median duration of breastfeeding (days [IQR]) 122 (98, 188) 182 (98, 337) 0.38
Infant median CD4% at time of confirmed diagnosis (IQR) 30 (22, 38) 29 (20, 36) 0.79
Infant median log10 viral load at time of confirmed diagnosis (copies/ml [IQR]) 5.4 (5.3, 5.8) 5.6 (5.2, 5.8) 0.82
Maternal Age (years [IQR]) 25 (23, 26) 22 (21, 26) 0.35
Maternal Education$secondary level 19 (76) 30 (61) 0.30
Maternal median CD4 counts at time of delivery (cells/mm
3 [IQR]) 316 (238, 454) 320 (192, 522) 0.47
Maternal median log10 viral load at time of delivery (copies/ml [IQR]) 4.9 (4.2, 5.2) 4.5 (3.8, 5.1) 0.24
Maternal intrapartum SD-NVP 12 (48) 30 (61) 0.33
Maternal antepartum AZT 4 (16) 14 (29) 0. 27
Maternal antiretroviral therapy
{ 8 (32) 4 (8) 0.02
Data are number of patients (%) unless stated otherwise.
SWEN=up to six weeks of extended-dose nevirapine; SD-NVP=single-dose nevirapine; AZT=zidovudine; IQR=interquartile range.
*All p-values generated using Fisher’s exact test for categorical variables and Mann-Whitney test for continuous variables.
{Maternal antiretroviral therapy was started after delivery in 11 of 12 women in both groups. Genotypes in 10 of these 11 corresponding infants were obtained prior to
initiation of maternal antiretroviral therapy.
doi:10.1371/journal.pone.0004096.t001
Nevirapine Resistance
PLoS ONE | www.plosone.org 3 January 2009 | Volume 4 | Issue 1 | e4096through clonal analysis (median 85 clones/patient) an additional
six of 15 SD-NVP-exposed infants diagnosed within the first six
weeks of life with NVP-R in whom cloning was successful. Cloning
was not successful in the one SWEN-exposed infant with wild-type
infection by standard population sequencing. Prevalence of NVP-
R in the SWEN group remained higher when low frequency
variants were also considered (92% of 12 vs. 59% of 29; p=0.06;
Figure 1; Table 2). This trend was also evident when only infants
infected during the first six weeks of life through peripartum/early-
breastfeeding were included, but this was not statistically
significant (100% of 4 vs. 53% of 15; p=0.25; Table 2).
Among in utero infected infants, 80% of 10 infants randomized to
SWEN received extended doses of NVP because of delays in
diagnosis. The proportion of in utero infected infants who received
SWEN or SD-NVP and who possessed NVP-R were 88% of 8 vs.
50% of 14, respectively (p=0.17) using standard population
sequencing, and 88% of 8 vs. 64% of 14, respectively (p=0.35) by
low frequency clonal analysis.
Because infants were serially tested for HIV infection through-
out the first year of life, we were able to assess the likelihood of
acquiring NVP-R if infected after six weeks of age through late
breast-milk transmission, a rate which was similar for both
intervention groups. Using standard population sequencing, 15%
of 13 infants who received SWEN and 15% of 20 infants who
received SD-NVP had drug resistance (p=1.00; Figure 2). The
proportion of infants infected through late-breastfeeding with
NVP-R at low frequencies was substantial but similar for SWEN
and SD-NVP groups when examined by clonal analysis (31% of
13 vs. 40% of 20; p=0.72; Figure 2; Table 2).
The types and number of NVP-R mutations were similar across
intervention groups, but differed by timing of infection (Table 2).
Among infants diagnosed in the first six weeks of life, the
predominant mutations detected by standard population sequencing
in SWEN and SD-NVP groups were Y181C (41% of 17 vs. 32% of
25; p=0.74) and K103N (18% of 17 vs. 20% of 25; p=1.00),
respectively(Table2).NVP-Rvariantspresentasmixtureswithwild-
type HIV were similar in both intervention groups (Table 2).
Seventy-one percent of infants infected in utero who received SWEN
had more than one NVP-R mutation compared to 29% who
received SD-NVP, but this difference was not statistically significant
(p=0.29; Table 2). However, NVP-R mutations in infants infected
through late-breastfeeding differed from those diagnosed in the first
six weeks of life. In the event of late-breastfeeding transmission,
Y188C/Hwasthemostcommonmutationpresentandwasfoundat
similar frequencies for infants in the SWEN and SD-NVP groups
(50% of 4 vs. 50% of 8; p=1.00; Table 2).
To further investigate breast-milk transmission of NVP-R HIV
among infants infected after six weeks of age, we examined HIV
genotypes six months after delivery in the seven available samples
from women exposed to SD-NVP who also transmitted HIV
through late-breastfeeding. All seven women and six of the seven
paired infants had wild-type HIV detectable by standard
population sequencing at the time of HIV diagnosis (Table 3).
However, NVP-R was present at low frequencies (73 clones/
patient) in four women (57%; median clonal frequency of 5.6%;
range 2.4%–14.5%). K103N was the most common mutation in
three of these four women (75%; Table 3). Although paired
maternal and infant sequences were phylogenetically related (data
not shown), mutations detected at low frequencies in infants
infected through late-breastfeeding were different from those
observed in their mothers (Table 3).
Differences in persistence of NVP-R mutations were assessed in a
smallnumberofinfantsexposedtoSWEN(n=5)orSD-NVP(n=5)
who had available plasma samples and also had NVP-R mutations
detected by standard population sequencing at the time of HIV
diagnosis (Table 4). Loss of detectable NVP-R mutations using
standard population sequencing was observed at a median of 12
months of age in infants who received SWEN (60% of 5) or SD-NVP
(80% of 5) (Table 4). However, most infants with wild-type HIV had
persistent NVP-R mutations at low frequencies (86%; median clonal
frequency of 3.1%; range 1.2%–12.8%), with similar rates and
mutation patterns for both intervention groups (Table 4).
Figure 1. SWEN and SD-NVP exposed HIV-infected infants diagnosed within the first six weeks of life with NVP-R. SWEN=up to six
weeks of extended-dose nevirapine; SD-NVP=single-dose nevirapine; NVP-R=nevirapine resistance. P-values generated using Fisher’s exact test.
doi:10.1371/journal.pone.0004096.g001
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Within the context of the SWEN trial to prevent breast-milk HIV
transmission, we found that prevalence of NVP-R was higher for
Indian infants who became subtype C HIV-infected in the first six
weeks of life despite receiving daily NVP than for those who had
received SD-NVP, a relationship that held even when low-frequency
variants were considered. Furthermore, we found a substantial
proportion of infants infected through breast-milk transmission
during the first year of life had NVP-resistant HIV when low
frequency variants were considered. The types of NVP-resistance
mutations were similar between the two intervention groups but
differed by timing of infection, where the Y181C variant was
predominant in infections occurring in the first six weeks of life
compared to the Y188C/H variant associated with late breast-milk
infections. The pattern of persistence of NVP-R was similar at both
population and low frequency levels at a median of one year of age,
although only a small number of infants were studied.
The high prevalence of NVP-R in this study is not surprising
given the long half-life of the drug [33] and the rapid selection of
NVP-R mutations observed in 45–87% of infants after SD-NVP
[12,34,13]. In our study, a significantly higher prevalence of NVP-
R mutations was found by standard population sequencing among
infants receiving SWEN (92%) and diagnosed with HIV infection
by six weeks of age than those receiving only SD-NVP (38%). The
prevalence of NVP-R remained higher with the SWEN regimen
with low frequency clonal analysis, but because of small sample
sizes we were not powered to detect a statistical difference. Others
have reported higher prevalence of NVP-R mutations among
Ugandan infants receiving extended-dose NVP while enrolled in
the SWEN trial and diagnosed with subtype A or D infection in
the first six weeks of life than for infants receiving SD-NVP [20].
In our analysis, daily dosing of NVP did not alter the dominant
NVP-resistant mutation selected in infants infected in the first six
of weeks of life. The Y181C variant remained dominant as
observed in studies of NVP-R following single-dose exposure in
infants [12,13] and in earlier studies of daily NVP monotherapy
for treatment of infected individuals [35,36].
Among infants born to SD-NVP exposed women and who escape
in-utero or peripartum/early-breastfeeding, the potential for acquir-
ing NVP-resistant HIV through breastfeeding continues, as NVP-R
mutationsare presentinbreast-milkinupto65%ofwomenexposed
to SD-NVP [37]. In our study, NVP-R did not differ by receipt of
SD-NVP or SWEN among infants infected through late-breastfeed-
ing. In both groups, 15% of infants had NVP-R detectable at
population levels,with31%ofSWENand40%ofSD-NVPexposed
infants acquiring NVP-R when low frequency variants were
considered. The predominant transmitted variants, here, were
Y188C/H and K103N, reflective of the most common mutations
found in women following SD-NVP exposure [12]. Maternal
HAART exposure also did not play a role in the resistance outcomes
we observed in these infants, as genotyping was done prior to
initiation of maternal HAART and therefore, not due to exposure to
suboptimal NVP concentrations in breast-milk. Furthermore, in the
fewsamplesavailableforanalysisfromwomenwho transmitted HIV
through breast-milk, the mutations present in plasma by standard
population sequencing or clonal analysis often differed from those
detected in their respective infants, highlighting the potential
compartmentalization of HIV variants within the breast and the
complexity of breast-milk transmission [38,37].
While it is well established that the use of single antiretroviral
agents in HIV-infected individuals virtually guarantees selection of
drug resistant virus, the efficacy of administering HAART to HIV-
infected women for prevention of breast-milk transmission is
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PLoS ONE | www.plosone.org 5 January 2009 | Volume 4 | Issue 1 | e4096currently under study [39]. However, preliminary data from one
study suggest that even with the administration of maternal
HAART, the risk of transmission of drug-resistant HIV through
breastfeeding remains. In the Kisumu Breastfeeding Study (KiBS) in
Kenya where NVP or protease-inhibitor based HAART was
administered to women from 34 weeks gestation through 6 months
postpartum, 67% of 24 infants had either lamivudine and/or NVP-
resistant HIV [40]. Since continued breastfeeding improves child
survival, even for HIV-infected infants [41], use of antiretroviral
drugsinthemotherandorinfanttopreventbreast-milktransmission
is currently the only available option for preventing HIV infection to
the infant in resource-constrained settings, but, as seen here, this
practice carries an inherent risk of drug resistance.
NVP-R as a consequence of prophylaxis to prevent MTCT is
highly relevant because treatment in resource-constrained settings
relies on NVP as a key component of HAART. NVP-R variants
arising after SD-NVP are eventually replaced in blood by wild-
type virus [12,13], and so NVP-based HAART remains the first-
line treatment regimen. In the context of extended NVP
prophylaxis, a higher proportion of SWEN-exposed Ugandan
infants had detectable NVP-R at population levels at six months of
age than did SD-NVP exposed infants (100% of 7 vs. 17% of 6)
[20]. However, in our study, NVP-R variants decayed in 70% of
infants exposed to SWEN or SD-NVP by a median of 12 months
of age, but remained at low frequencies in 86% of infants. The
clinical implications for infants of this NVP-R and its persistence at
low frequencies, however, are unclear. One small study showed a
higher risk of virologic failure for SD-NVP-exposed than for
unexposed infants on NVP-based HAART initiated at a median of
8 months [19]. Time to treatment initiation following prophylaxis
Figure 2. SWEN and SD-NVP exposed infants infected with HIV after six weeks of age through late-breastfeeding with NVP-R.
SWEN=up to six weeks of extended-dose nevirapine; SD-NVP=single-dose nevirapine; NVP-R=nevirapine resistance. P-values generated using
Fisher’s exact test.
doi:10.1371/journal.pone.0004096.g002
Table 3. Late breast-milk transmission of NVP-R HIV in seven mother-infant pairs.
Infant
Intervention Infant ID
Infant Age at
HIV Diagnosis
(Months)
Infant Genotype at
Diagnosis (Population
Sequencing)
Infant Genotype
at Diagnosis
(Clonal Analysis)
Maternal Genotype
at 6 Months Postpartum
(Population Sequencing)
Maternal Genotype
at 6 Months Postpartum
(Clonal Analysis)
SWEN 6 2.5 WT Y188H WT K103N
38 2.5 WT WT WT K103N
SD-NVP 10 2.5 WT/G190A n/a* WT K103N
20 6 WT WT WT Y181C, Y188C
61 9 WT WT WT WT
40 12 WT Y188H WT WT
74 12 WT WT WT WT
NVP-R=nevirapine resistance; WT=wild-type HIV; SWEN=up to six weeks of extended-dose of nevirapine; SD-NVP=single-dose nevirapine; n/a=not applicable.
*G190A detected as a mixture with wild-type HIV using standard population sequencing therefore, cloning was not performed in this patient.
doi:10.1371/journal.pone.0004096.t003
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PLoS ONE | www.plosone.org 6 January 2009 | Volume 4 | Issue 1 | e4096in infants may also be critical, as SD-NVP exposed women who
initiated NVP-based HAART less than six months after delivery had
a higher risk of virologic failure than those who started treatment
after six months [19]. Recent evidence showed that early therapy in
HIV-infected infants can improve survival [42], which has led the
WHO to recommend early HAART for all HIV-infected infants less
than 12 months of age [43]. Therefore, if the findings on persistence
ofNVP-RfromtheIndianandUgandanSWENtrialsareconfirmed
in a large number of subtype A, C, or D HIV-infected infants, then
this will influence the use of NVP as part of first line therapy, if
extended NVP prophylaxis is implemented.
Our study has some limitations. First, unlike other studies of SD-
NVP prophylaxis, we were unable to test for NVP-R at a fixed time
point, although the median age at genotyping for infants infected in
utero or through peripartum/early-breastfeeding was similar to other
published studies. Assessing NVP-R at low frequencies using clonal
analysis is limited bythe number of clones required to detect NVP-R
variants and may underestimate resistance at frequencies ,5%.
However, cloning did allow comprehensive assessment at all eight
known sites of NVP-R in HIV reverse transcriptase. In addition, due
to the limited number of maternal samples available for genotyping
at six months and lack of breast-milk samples, drug resistance
mutations present in plasma and breast-milk could not be
determined or correlated with HIV transmission.
In summary, our results suggest the extended-dose NVP regimen
used in the SWEN trial to prevent breast-milk transmission of HIV
does carry a higher risk of infection with drug resistant virus than
does SD-NVP in subtype C-infected infants, and that the risk of
infection with NVP-R variants at low frequencies continues through
the first year of life with breastfeeding. Given the high mortality
associated with pediatric HIV infection in the first year of life, the
complexities of early infant diagnosis, and limited resources for
initiating HAART in infants in settings where breastfeeding itself is
critical for survival, the primary goal should be to prevent
peripartum and breast-milk transmission with infant antiretroviral
prophylaxis. As other prevention options become available, this
increased risk could be revisited.
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